

TRAP230 Polyclonal Antibody

Description

| | |
|--------------------------------|---|
| Product type | Primary Antibody |
| Code | BT-AP09181 |
| Host | Rabbit |
| Isotype | IgG |
| Size | 20ul, 50ul, 100ul |
| Immunogen | The antiserum was produced against synthesized peptide derived from human MED12. AA range:611-660 |
| Mol wt | 247334 |
| Species reactivity | Human |
| Clonality | Polyclonal |
| Recommended application | IHC-p, WB, ELISA |
| Concentration | 1 mg/ml |
| Full name | TRAP230 Antibody |
| Synonyms | MED12; ARC240; CAGH45; HOPA; KIAA0192; TNRC11; TRAP230; Mediator of RNA polymerase II transcription subunit 12; Activator-recruited cofactor 240 kDa component; ARC240; CAG repeat protein 45; Mediator |

This product is for research use only, not for use in human, therapeutic or diagnostic procedure.

Background

The initiation of transcription is controlled in part by a large protein assembly known as the preinitiation complex. A component of this preinitiation complex is a 1. MDa protein aggregate called Mediator. This Mediator component binds with a CDK8 subcomplex which contains the protein encoded by the gene, mediator complex subunit 12 (MED12), along with MED13, CDK8 kinase, and cyclin C. The CDK8 subcomplex modulates Mediator-polymerase II interactions and thereby regulates transcription initiation and reinitiation rates. The MED12 protein is essential for activating CDK8 kinase. Defects in this gene cause X-linked Opitz-Kaveggia syndrome, also known as FG syndrome, and Lujan-Fryns syndrome.

Recommended Dilution


WB: 1: 500 - 2000

ELISA: 1: 5000

IHC: 1: 100 - 1: 300

Not yet tested in other applications.

Images



Immunohistochemistry analysis of paraffin-embedded human lung carcinoma, using MED12 Antibody. The picture on the right is blocked with the synthesized peptide.

Storage

-20°C for one year